HCPCS Level II drug code
J0696 — Injection, ceftriaxone sodium, per 250 mg
In short
J0696 is the HCPCS Level II code for injection, ceftriaxone sodium, per 250 mg. CMS assigns NDCs for Ceftriaxone and Ceftriaxone in D5W to it. One billing unit is 250 mg. The Medicare Part B payment limit is $0.39 per unit (October 1, 2026 through December 31, 2026).
Code
Med-Code curatedHCPCS codeJ0696
Billing unit250 mg
- Descriptor
- Injection, ceftriaxone sodium, per 250 mg
- Code set
- HCPCS Level II, maintained by CMS
- Category
- Antibiotic / Cephalosporin
Medicare Part B payment limit
CMS ASP filePayment limit per unit$0.39
Per250 mg
Coinsurance20%
Effective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Units and claim line
Units = dose given ÷ 250 mg. For example, 25000 mg is 100 units. Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.
Enter the dose given to build the claim line.
Drugs mapped to J0696
FDA-listed products billed under J0696
Finished products in the FDA NDC Directory whose brand or single active ingredient, and route, match this code’s entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Ceftriaxone Sodium | Ceftriaxone sodium 2 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | Hospira, Inc | 0409-7335 |
| Ceftriaxone | Ceftriaxone sodium 10 g/1 | Injection, Powder, For solutionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9678 |
| Ceftriaxone Sodium | Ceftriaxone sodium 10 g/100mL | Injection, Powder, For solutionIntravenous | Hospira, Inc | 0409-7334 |
| Ceftriaxone Sodium | Ceftriaxone sodium 250 mg/1 | Injection, Powder, For solutionIntramuscular, Intravenous | Qilu Pharmaceutical Co., Ltd. | 67184-1005 |
| Ceftriaxone Sodium | Ceftriaxone sodium 500 mg/1 | Injection, Powder, For solutionIntramuscular, Intravenous | Sportpharm LLC | 85766-128 |
| Ceftriaxone Sodium | Ceftriaxone sodium 500 mg/1 | Injection, Powder, For solutionIntramuscular, Intravenous | Qilu Pharmaceutical Co., Ltd. | 67184-1006 |
| Ceftriaxone Sodium | Ceftriaxone sodium 1 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | Qilu Pharmaceutical Co., Ltd. | 67184-1007 |
| Ceftriaxone Sodium | Ceftriaxone sodium 2 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | Qilu Pharmaceutical Co., Ltd. | 67184-1008 |
| Ceftriaxone | Ceftriaxone sodium 2 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | 0143-9856 |
| Ceftriaxone Sodium | Ceftriaxone sodium 10 g/100mL | Injection, Powder, For solutionIntravenous | Hospira, Inc | 0409-7334 |
| Ceftriaxoneceftriaxone sodium | Ceftriaxone sodium 100 g/1 | Injection, Powder, For solutionIntravenous | Samson Medical Technologies, LLC | 66288-6100 |
| Ceftriaxone | Ceftriaxone sodium 1 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | 0143-9857 |
| Ceftriaxone | Ceftriaxone sodium 500 mg/1 | Injection, Powder, For solutionIntramuscular, Intravenous | WG Critical Care, LLC | 44567-700 |
| Ceftriaxone | Ceftriaxone sodium 1 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | WG Critical Care, LLC | 44567-701 |
| Ceftriaxone | Ceftriaxone sodium 1 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | WG Critical Care, LLC | 44567-701 |
| Ceftriaxone | Ceftriaxone sodium 2 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | WG Critical Care, LLC | 44567-702 |
| Ceftriaxone | Ceftriaxone sodium 2 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | WG Critical Care, LLC | 44567-702 |
| Ceftriaxone | Ceftriaxone sodium 10 g/1 | Injection, Powder, For solutionIntravenous | WG Critical Care, LLC | 44567-703 |
| Ceftriaxone Sodium | Ceftriaxone sodium 2 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | Hospira, Inc | 0409-7335 |
| Ceftriaxone | Ceftriaxone sodium 500 mg/1 | Injection, Powder, For solutionIntramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | 0143-9858 |
| Ceftriaxone | Ceftriaxone sodium 1 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | Fresenius Kabi USA, LLC | 63323-346 |
| Ceftriaxone | Ceftriaxone sodium 250 mg/1 | Injection, Powder, For solutionIntramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | 0143-9859 |
| Ceftriaxone Sodium | Ceftriaxone sodium 250 mg/1 | Injection, Powder, For solutionIntramuscular, Intravenous | A-S Medication Solutions | 50090-2444 |
| Ceftriaxone Sodium | Ceftriaxone sodium 2 g/1 | Injection, Powder, For solutionIntravenous | Hospira, Inc | 0409-7336 |
| Ceftriaxone And Dextroseceftriaxone | Ceftriaxone sodium 1 g/50mL | Injection, SolutionIntravenous | B. Braun Medical Inc. | 0264-3153 |
All NDCs for these drugs
NDCs billed under J0696
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 61 NDCs to J0696 for Ceftriaxone and Ceftriaxone in D5W. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Ceftriaxone | 00143-9678-01 | Hikma Pharmaceuticals USA Inc. | 1 | 40 |
| Ceftriaxone | 00143-9856-25 | Hikma Pharmaceuticals USA Inc. | 25 × 1 | 200 |
| Ceftriaxone | 00143-9857-25 | Hikma Pharmaceuticals USA Inc. | 25 × 1 | 100 |
| Ceftriaxone | 00143-9858-25 | Hikma Pharmaceuticals USA Inc. | 25 × 1 | 50 |
| Ceftriaxone | 00143-9859-25 | Hikma Pharmaceuticals USA Inc. | 25 × 1 | 25 |
| Ceftriaxone | 00409-7332-01 | Pfizer Inc | 10 × 1 | 40 |
| Ceftriaxone | 00409-7332-20 | Pfizer Inc | 10 × 1 | 40 |
| Ceftriaxone | 00409-7333-04 | Pfizer Inc | 10 × 1 | 40 |
| Ceftriaxone | 00409-7333-49 | Pfizer Inc | 10 × 1 | 40 |
| Ceftriaxone | 00409-7334-10 | Pfizer Inc | 1 | 40 |
| Ceftriaxone | 00409-7334-20 | Pfizer Inc | 1 | 40 |
| Ceftriaxone | 00409-7335-03 | Pfizer Inc | 10 × 1 | 80 |
| Ceftriaxone | 00409-7335-20 | Pfizer Inc | 10 × 1 | 80 |
| Ceftriaxone | 00409-7336-04 | Pfizer Inc | 10 × 1 | 80 |
| Ceftriaxone | 00409-7337-01 | Pfizer Inc | 10 × 1 | 10 |
| Ceftriaxone | 00409-7337-20 | Pfizer Inc | 10 × 1 | 10 |
| Ceftriaxone | 00409-7338-01 | Pfizer Inc | 10 × 1 | 20 |
| Ceftriaxone | 00409-7338-20 | Pfizer Inc | 10 × 1 | 20 |
| Ceftriaxone | 00781-3206-85 | Sandoz Inc. | 1 | 1 |
| Ceftriaxone | 00781-3206-95 | Sandoz Inc. | 10 × 1 | 10 |
| Ceftriaxone | 00781-3207-85 | Sandoz Inc. | 1 | 2 |
| Ceftriaxone | 00781-3207-95 | Sandoz Inc. | 10 × 1 | 20 |
| Ceftriaxone | 00781-3208-85 | Sandoz Inc. | 1 | 4 |
| Ceftriaxone | 00781-3208-95 | Sandoz Inc. | 10 × 1 | 40 |
| Ceftriaxone | 00781-3209-95 | Sandoz Inc. | 10 × 1 | 80 |
| Ceftriaxone | 00781-3210-46 | Sandoz Inc. | 1 | 40 |
| Ceftriaxone | 25021-0105-10 | Sagent Pharmaceuticals | 25 × 1 | 50 |
| Ceftriaxone | 25021-0105-66 | Sagent Pharmaceuticals | 25 × 1 | 50 |
| Ceftriaxone | 25021-0106-10 | Sagent Pharmaceuticals | 25 × 1 | 100 |
| Ceftriaxone | 25021-0106-67 | Sagent Pharmaceuticals | 25 × 1 | 100 |
| Ceftriaxone | 25021-0107-20 | Sagent Pharmaceuticals | 25 × 1 | 200 |
| Ceftriaxone | 25021-0107-68 | Sagent Pharmaceuticals | 25 × 1 | 200 |
| Ceftriaxone | 25021-0108-69 | Sagent Pharmaceuticals | 1 | 40 |
| Ceftriaxone | 25021-0108-99 | Sagent Pharmaceuticals | 1 | 40 |
| Ceftriaxone | 44567-0700-25 | WG Critical Care, LLC | 25 × 1 | 50 |
| Ceftriaxone | 44567-0701-25 | WG Critical Care, LLC | 25 × 1 | 100 |
| Ceftriaxone | 44567-0701-95 | WG Critical Care, LLC | 25 × 1 | 100 |
| Ceftriaxone | 44567-0702-25 | WG Critical Care, LLC | 25 × 1 | 200 |
| Ceftriaxone | 44567-0702-95 | WG Critical Care, LLC | 25 × 1 | 200 |
| Ceftriaxone | 44567-0703-01 | WG Critical Care, LLC | 1 | 40 |
| Ceftriaxone | 50090-0944-00 | A-S Medication Solutions | 10 × 1 | 20 |
| Ceftriaxone | 50090-0945-00 | A-S Medication Solutions | 10 × 1 | 40 |
| Ceftriaxone | 50090-1875-00 | A-S Medication Solutions | 10 × 1 | 10 |
| Ceftriaxone | 50090-2444-00 | A-S Medication Solutions | 1 | 1 |
| Ceftriaxone | 50090-3810-01 | A-S Medication Solutions | 10 × 1 | 40 |
| Ceftriaxone | 50090-3838-00 | A-S Medication Solutions | 1 | 2 |
| Ceftriaxone | 50090-4689-00 | A-S Medication Solutions | 10 × 1 | 10 |
| Ceftriaxone | 60505-6148-04 | Apotex Corp | 10 × 1 | 40 |
| Ceftriaxone | 60505-6149-04 | Apotex Corp | 10 × 1 | 80 |
| Ceftriaxone | 60505-6150-05 | Apotex Corp | 1 | 40 |
| Ceftriaxone | 60505-6151-01 | Apotex Corp | 10 × 1 | 10 |
| Ceftriaxone | 60505-6151-04 | Apotex Corp | 1 | 1 |
| Ceftriaxone | 60505-6152-01 | Apotex Corp | 10 × 1 | 20 |
| Ceftriaxone | 60505-6152-04 | Apotex Corp | 1 | 2 |
| Ceftriaxone | 63323-0346-10 | FreseniUS Kabi USA, LLC | 25 × 1 | 100 |
| Ceftriaxone | 72572-0061-25 | Civica, Inc. | 25 × 1 | 100 |
| Ceftriaxone | 72572-0062-25 | Civica, Inc. | 25 × 1 | 200 |
| Ceftriaxone in D5W | 00264-3153-11 | B. Braun Medical Inc. | 24 × 1 | 96 |
| Ceftriaxone in D5W | 00264-3155-11 | B. Braun Medical Inc. | 24 × 1 | 192 |
| Ceftriaxone in D5W | 00338-5002-41 | Baxter Healthcare Corporation | 24 × 50 | 96 |
Showing 60 of 61. The full list is in the CMS crosswalk file.
J0696: common questions
- Is J0696 a CPT code?
- No. J0696 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
- What NDCs are billed under J0696?
- CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 61 NDCs under J0696, for Ceftriaxone and Ceftriaxone in D5W. The table on this page shows each one with its billing units per package.
- What is the Medicare payment limit for J0696?
- $0.39 per 250 mg, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.
- What is one billing unit of J0696?
- One unit of J0696 is 250 mg, as stated in the code's descriptor. Units to report = dose given ÷ 250 mg. J-code billing units.